Bacterial Translocation Markers as Predictors of Infectious and Inflammatory Complications in Acute Bowel Obstruction

Summary

Despite modern approaches to the diagnosis and treatment of acute bowel obstruction (ABO), postoperative mortality ranges from 5 to 32%, and complications occur up 23% of cases. One of the formidable infectious and inflammatory complications of ABO is sepsis. The main component of the development of sepsis in ABO is bacterial translocation (BT). BT is the migration of intestinal bacteria or their products through the intestinal mucosa into the mesenteric lymph nodes and further into normally sterile tissues and organs.

Today there are several methods for detecting BT:

1. direct method - the detection of 16s rRNA (ribosomal ribonucleic acid) in mesenteric lymph nodes (MLN);
2. indirect method - the detection of serum lipopolysaccharide-binding protein (LBP) and presepsin (Soluble CD14 subtype or sCD14-ST).

The aim of this study is to determine the diagnostic and prognostic significance of bacterial translocation as a predictor of the complications development in patients with malignant and benign acute bowel obstruction by assessing the relationship of biomarkers in the systemic circulation (LBP, sCD14-ST) with the detection of microorganism genes (16s rRNA) in mesenteric lymph nodes.

Conditions

• Intestinal Obstruction
• Colorectal Cancer
• Post-Op Complication
• Systemic Inflammatory Response Syndrome
• Colon Tumor

Interventions

DIAGNOSTIC_TEST

LBP

Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

DIAGNOSTIC_TEST

sCD14-ST

Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

DIAGNOSTIC_TEST

16s rRNA

Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.

Sponsors & Collaborators

• Ministry of Education and Science, Republic of Kazakhstan

  collaborator OTHER_GOV

• Karaganda Medical University

  lead OTHER

Principal Investigators

• Yemek Turgunov, Pr. · NJSC Karaganda Medical University

• Alina Ogizbayeva, PhD student · NJSC Karaganda Medical University

• Lyudmila Akhmaltdinova, PhD · NJSC Karaganda Medical University

• Kairat Shakeyev, Pr. · NJSC Karaganda Medical University

• Dmitry Matyushko, PhD · Multidisciplinary hospital No. 1 of Karaganda

• Miras Mugazov, PhD · NJSC Karaganda Medical University

• Asylbek Zhumakaev, Master · Multidisciplinary hospital No. 3 of Karaganda

• Irina Kadyrova, PhD · NJSC Karaganda Medical University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-03-01

Primary Completion

2023-10-31

Completion

2023-12-31

Countries

• Kazakhstan

Study Locations